【摘要】 目的:评价晚期鼻咽癌(NPC)患者应用紫杉醇与顺铂联合化疗的临床疗效及安全性。方法:2003年6月~2005年8月采用紫杉醇联合顺铂治疗晚期鼻咽癌48例。中位化疗周期数3周期(2周期~5周期)。紫杉醇(PTX)135mg/m2,静脉滴注d1;顺铂(DDP)80mg/m2,静脉滴注d1~2,21天为一个周期。结果:可评价疗效48例,CR6例(12.5%),PR19例(39.6%),NC 14例(29.1%),PD9例(18.7%),总有效率(CR+PR)52.1%,中位缓解期(DFS)为6.5(2~12)个月,中位肿瘤进展时间(TTP)7.6(2~14)个月。主要毒性为骨髓抑制、胃肠道反应和关节肌肉疼痛,Ⅲ度~Ⅳ度白细胞减少发生率为18.7%,无严重并发症发生。结论:紫杉醇联合顺铂治疗晚期鼻咽癌有较好的疗效,且不良反应可以耐受。更多还原

【Abstract】 Objective: To evaluate the clinical response of paolitexel and cisplatin for patients with advanced nasopharyngeal carcinoma,and to assess the safety of paclitaxel based combination chemotherapy.Methods: From June 2003 to August 2005,48 patients with advanced nasopharyngeal carcinoma were treated by alliance of paclitaxel and cisplatin.The mean number of cycles was 3(range 2~5),PTX 135mg/m2 d1,ivgtt;DDP 80mg/m2 d1~2,ivgtt.The cycle was repeated every 21 days.Results: The overall response rate(CR+PR) was 52.1%(CR 6 cases,PR 19 cases,NC 14 cases and PD 9 cases).The mean time of DFS was 6.5 months(range 2 to 12 months).The median TTP was 7.6 months(range 2 to 14 months).The main side effects included bone marrow depression,emesis,nausea,and pain of joint and muscle.The rate of leukocytopenia with Ⅲ to Ⅳ degree was 18.7%.No severe complications happened.Conclusion: The regimen of paclitaxel plus cisplatin is active in treatment of advanced nasopharyngeal carcinoma with an acceptable drug tolerance.更多还原